As of June 12, 2018 our Privacy Policy has been updated. For individuals in the European Union, CIL uses cookies on this website. Please review the new privacy statement to see how. By continuing to use this website you agree to us using cookies in accordance with our privacy statement. Click here for the new privacy statement..OK

Products
Research Products
Amino Acids Bile Acids Biochemical Pathways Biological Standards Buffers and Reagents Carbohydrates CellFree Protein Expression Cell Growth Media Chemical Tagging Reagents Deuterated Reagents for ElectronicsDeuterated Reagents for PharmaceuticalsElements and Compounds Fatty Acids & Lipids Drug Standards Gases cGMP ProductsGlycans IROA Biochemical Quantitation Kits Key Metabolite Standards a-Keto Acids13C Metabolic Probes Metabolomics Mixes and Kits Metabolites & Substrates Methyl Labeling Kits & Amino Acids		 Metabolomics & Cellular 
MetabolismMicrobiological & Pyrogen Tested Mouse Express® Mouse Feed MRI/MRS Products MRM PeptiQuant™ Assay Kits MS/MS StandardsNMR Solvents and ConsumablesNucleic AcidsOrganic Acids & Conjugate Salts Protein StandardsProtein Reagents15N SaltsSILAC ReagentsSpirulinaSteroids and HormonesSynthetic IntermediatesVitaminsWater		 Environmental Contaminant Standards
Cyanotoxin Standards
Dioxin & Furan Individual Standards Dioxin & Furan Method Standards, Standard Mixtures, and Reference Materials PCB Standards & Standard MixturesFlame Retardants Dioxin/Furan Plus PCB Standard Mixtures Polycyclic Aromatic Hydrocarbon (PAH) Standards and Standard Mixtures Priority Pollutant Standard Mixtures Priority Pollutant, Endocrine Disruptor, and Chemical Contaminant Standards
Pesticides, Herbicides, and Metabolites Standards PPCPs Phthalate & Phthalate Metabolite Standards Chemical Weapon Metabolite Standards Per- and Polyfluoroalkyl Substances (PFAS)Stockholm Treaty Compounds

 

New Products

Corporate Overview


Eurisotop Responds to Market Demand for Deuterated Chloroform

September 22, 2020

Saclay, France

Eurisotop, a wholly owned subsidiary of Cambridge Isotope Laboratories, Inc. (CIL), announced a capacity expansion of its deuterated chloroform production. Since its acquisition by CIL in 2001, Eurisotop has become a leading producer of deuterated NMR solvents and is the premier supplier of CIL stable isotope-labeled compounds in Europe. Eurisotop initially operated one reactor that produced six tons of deuterated chloroform per year. This new expansion consisted of adding a second reactor (twin reactors) and when operating simultaneously and continuously can produce tens of tons of product per year.

“Cambridge Isotope had recently conducted an analysis of a broad sampling of deuterated chloroform products from a number of global suppliers. The production process and technology at Eurisotop was a clear standout in terms of quality and repeatability. This investment makes the CIL Group the world’s largest supplier of deuterated chloroform. By increasing capacity, Eurisotop will have the capability to meet all customer requirements with the world’s highest quality product. The combination of Eurisotop and CIL in the United States make the CIL Group the clear supplier of choice for researchers across the globe,” states Cliff Caldwell, CEO of CIL.

Deuterated chloroform (chloroform-d) is the most commonly and widely used solvent in NMR spectroscopy. The growing global demand of deuterated chloroform required this essential expansion.

“This new expansion is designed to provide a better-quality, higher-purity product for the customer that is guaranteed to be without acidity and phosgene, with a very-low water content,” adds Eurisotop Production Manager Philippe Thourel. “The expansion will enable the group to meet the growing needs of our customers and provide a wide range of products to meet all requirements.”

 

About Cambridge Isotope Laboratories, Inc.  

CIL is the world’s largest manufacturer and global supplier of stable isotopes and stable isotope-labeled compounds used in research, environmental, neonatal, pharmaceutical, medical diagnostic, OLED, and industrial markets. CIL is an operating business owned by Otsuka Pharmaceuticals. The CIL business consists of two facilities in the Boston, MA, area; a large isotope-enrichment production plant in Xenia, OH; CIL China; CIL Canada; ABX in Dresden, Germany; and Eurisotop in Saclay, France.  

For more information on CIL, visit isotope.com.  

Back to list

News Index

CIL News| Cambridge Isotope Laboratories
metabolic substrates, isotope labeling, SILAC Amino Acids, protein standards, SILAC, Metabolic Labeling, NMR Tubes, Nucleic Acid Synthesis, alpha keto acids, Cell-Free Protein Expression, deuterated compounds, biomolecular nor, stable isotope, Hyperpolarization, nuclear medicine isotopes, Stable Isotopes, protein NMR, Protein Reagents, Deuterium labeled compounds, minimal media, Heavy Isotopes, metabolic research, custom synthesis, mass spectrometry, list of stable isotopes, Quantitative Proteomics, Nuclear Medicine, Metabolomics, food testing, Solid State NMR, proteomics, Membrane Proteins, mass spectrometry isotopes, Nucleic Acid, NMR, Protein Expression, material testing, Peptide Synthesis
CIL and its people have been committed to high quality stable isotope labeled products, superior customer service, innovative new products and a breadth of product lines.